<DOC>
	<DOCNO>NCT02232113</DOCNO>
	<brief_summary>The response Continuous Erythropoietic Receptor Activator ( CERA ) different dose interval survey influence factor : We aim evaluate good clinical response achieve different dose interval fix dose CERA . We expect study determine dosing schedule well clinical response CERA identify associate factor predict cost-effectiveness CERA maintenance hemodialysis ( HD ) patient Taiwan .</brief_summary>
	<brief_title>Frequent Dosing CERA Improves Nutrition Inflammation Hemodialysis Patients</brief_title>
	<detailed_description>We include HD patient stable hematocrit ( 30~36 % ) intravenous administration CERA 100 μg monthly two month . Then shift receive CERA 50μg twice monthly anther two month finally shift back receive CERA 100 μg monthly additional two month . Then measure compare erythropoietic response ( hematocrit , hemoglobin ) , profile iron status well nutritional status inflammatory marker among study subject every two month total 6 month . Those bleed receive surgery blood transfusion exclude .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Malnutrition</mesh_term>
	<criteria>HD patient stable hematocrit ( 30~36 % ) intravenous administration CERA 100 μg monthly two month . HD patient exclude due active bleeding ( major trauma , gastric ulcer bleeding , surgery ) , blood transfusion administration additional erythropoietic stimulating agent ( ESA ) CERA within followup period study perod 6 month . People discontinue CERA ESA also exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>malnutrition , inflammation , anemia ( MIA ) syndrome ,</keyword>
	<keyword>hemodialysis ,</keyword>
	<keyword>erythropoietin stimulate agent ( ESA ) ,</keyword>
	<keyword>cost-effectiveness ,</keyword>
	<keyword>pharmacokinetics ,</keyword>
	<keyword>endothelial dysfunction</keyword>
</DOC>